Earnings summaries and quarterly performance for AMARIN CORP PLC\UK.
Executive leadership at AMARIN CORP PLC\UK.
Aaron D. Berg
Detailed
President and Chief Executive Officer
CEO
DK
David Keenan, Ph.D.
Detailed
Executive Vice President, Chief Operating Officer
JN
Jonathan N. Provoost
Detailed
Executive Vice President, Chief Legal & Compliance Officer and Secretary
PL
Peter L. Fishman
Detailed
Senior Vice President, Chief Financial Officer
SB
Steven B. Ketchum, Ph.D.
Detailed
Executive Vice President, President of R&D and Chief Scientific Officer
Board of directors at AMARIN CORP PLC\UK.
Research analysts who have asked questions during AMARIN CORP PLC\UK earnings calls.
JF
Jessica Fye
JPMorgan Chase & Co.
3 questions for AMRN
Also covers: ALKS, ALNY, ASND +23 more
Mazahir Alimohamed
Leerink Partners
2 questions for AMRN
Also covers: AKBA, AQST, LNTH +2 more
PC
Paul Choi
Goldman Sachs
2 questions for AMRN
Also covers: ARVN, ASND, BBIO +13 more
Daniel
Craig-Hallum
1 question for AMRN
Also covers: ARVN, ASUR, CTOS +3 more
KC
Kyuwon Choi
Goldman Sachs
1 question for AMRN
Also covers: ASND, BHVN, CYTK +9 more
MA
Maizi Ali Mohamed
Leerink Partners LLC
1 question for AMRN
Michael
TD Cowen
1 question for AMRN
Also covers: AKBA, APH, GLBE +5 more
Recent press releases and 8-K filings for AMRN.
Amarin Reports Q4 and Full Year 2025 Financial Results and Strategic Progress
AMRN
Earnings
Guidance Update
New Projects/Investments
- Amarin reported Q4 2025 total net revenue of $49.2 million and a narrowed operating loss of $2.3 million (excluding restructuring charges), driven by a 31% decline in total operating expenses.
- For the full year 2025, the company achieved a significant reduction in operating expenses, generated positive cash flow, and ended the year with a debt-free balance sheet and $303 million in cash and investments as of December 31, 2025.
- The global restructuring plan realized approximately half of the estimated $70 million in operating expense savings by December 31, 2025, with the full benefit expected by June 30, 2026.
- The exclusive long-term partnership with Recordati, which commenced in Q3 2025 for VAZKEPA commercialization in Europe, included a $25 million upfront cash payment and eligible future milestone payments totaling up to $150 million.
- Amarin anticipates generating positive cash flow for the full year 2026, supported by its U.S. franchise and the new international business model with a significantly improved operating expense profile.
3 days ago
Amarin Reports Q4 2025 Financial Results and Strategic Progress
AMRN
Earnings
Guidance Update
New Projects/Investments
- Q4 2025 total net revenue was $49.2 million.
- For full year 2025, Amarin achieved a significant reduction in operating expenses, generated positive cash flow from operations of $7 million, and maintained a debt-free balance sheet with $303 million in cash and investments.
- The global restructuring plan resulted in a 31% decline in total operating expenses in Q4 2025 , with approximately half of the estimated $70 million in total operating expense savings realized by year-end 2025.
- The company established an exclusive long-term partnership with Recordati in mid-2025 to commercialize VAZKEPA in Europe, which included a $25 million upfront cash payment and eligible future milestone payments up to $150 million.
- Amarin anticipates generating positive cash flow for the full year in 2026.
3 days ago
Amarin Reports Q4 and Full Year 2025 Financial Results and Strategic Progress
AMRN
Earnings
Guidance Update
New Projects/Investments
- Amarin reported Q4 2025 net revenue of $49.2 million and FY 2025 revenue of $213.6 million.
- The company ended 2025 with $303 million in aggregate cash and investments and no long-term debt, having achieved positive cash flow earlier than anticipated.
- Amarin completed restructuring initiatives, realizing approximately 50% of the anticipated $70 million in OPEX savings in FY 2025, with positive impacts expected to become increasingly evident starting in 2026.
- In June 2025, Amarin entered an exclusive, long-term license and supply agreement with Recordati for VAZKEPA in 59 countries, primarily in Europe, which included a $25 million upfront cash payment and potential future milestone payments up to $150 million.
- A significant market opportunity is anticipated following the June 2025 FDA update to fenofibrate labeling, which highlighted that these medications are not associated with any proven cardiovascular benefits.
3 days ago
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
AMRN
Earnings
Layoffs
- Amarin reported Total Net Revenue of $49.2 million for Q4 2025, representing a 21% decrease compared to Q4 2024, primarily due to declines in Rest-of-World sales, a lower U.S. net selling price, and the transition of European sales activities.
- The company significantly narrowed its Operating Loss to $(6.3) million in Q4 2025, an 88% improvement from Q4 2024, and its Net Loss improved to $(1.2) million, a 97% improvement.
- These financial improvements were driven by strategic initiatives and a re-imagined operating model, which resulted in $31 million of expected cost savings from restructuring initiatives, with $36.2 million in restructuring charges incurred for the full year 2025.
- Amarin concluded 2025 with $302.6 million in cash and investments and no debt, achieving positive cash flow in Q4 2025 ahead of schedule.
3 days ago
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments
AMRN
Earnings
Guidance Update
New Projects/Investments
- Amarin Corporation plc announced preliminary unaudited financial highlights for Q4 and FY 2025, reporting a year-end 2025 cash balance of $303 million, an increase of $16 million from Q3 2025, and achieving positive cash flow in Q4 2025 ahead of prior expectations.
- The company expects Q4 2025 net revenue to range between $48 - $53 million and FY 2025 net revenue to range between $212 - $217 million.
- Amarin has realized approximately 50% of the $70 million in estimated OPEX savings from its 2025 restructuring and is on track to achieve the full estimated benefit by June 30, 2026.
- Key operational accomplishments include sustaining VASCEPA's U.S. market leadership with over 50% of IPE prescriptions and completing the transition to a fully partnered commercialization model across all international markets, including a partnership with Recordati S.p.A. for VAZKEPA in 59 countries.
Jan 8, 2026, 12:05 PM
Amarin Reports Q3 2025 Financial Results and Strategic Progress
AMRN
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Amarin reported total net revenue of $49.7 million in Q3 2025, a 17% increase year-over-year, driven by a 34% increase in U.S. net product revenue to $40.9 million.
- The company significantly improved its financial discipline, with a Q3 2025 operating loss of $11.1 million, a 56% reduction from Q3 2024, and an operating margin of negative 22%, up from negative 60% in the prior year.
- Amarin has transitioned to a fully partnered commercial model across international ex-U.S. markets, notably with Recordati in Europe, and implemented an organizational restructuring expected to yield $70 million in OpEx savings over the next year.
- The company anticipates achieving positive free cash flow in 2026 and ended Q3 2025 with $286.6 million in cash and investments and no debt.
- The FDA's recent revision of phenofibrate labeling, stating no cardiovascular benefit, is viewed as a critical step toward shifting clinical practice and an opportunity for VASCEPA, which has proven outcomes.
Oct 29, 2025, 12:00 PM
Amarin Reports Q3 2025 Financial Results with Revenue Growth and Improved Operating Loss
AMRN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Amarin reported total net revenue of $49.7 million for Q3 2025, marking a 17% increase year-over-year, primarily driven by a 34% rise in U.S. net product revenue to $40.9 million.
- The company's operating loss significantly improved to $11.1 million, a 56% reduction from Q3 2024, with operating margin improving to -22% from -60% in the prior year, largely due to a 47% reduction in SG&A from global restructuring.
- Amarin is progressing with its fully partnered commercial model across international ex-U.S. markets, with the European transition to Recordati on track for completion by year-end 2025.
- The company ended the quarter with $286.6 million in cash and investments and no debt, and anticipates achieving positive free cash flow in 2026.
Oct 29, 2025, 12:00 PM
Amarin Reports Q3 2025 Financial Results and Progresses on Partnered Commercial Model
AMRN
Earnings
Revenue Acceleration/Inflection
Layoffs
- Amarin reported Q3 2025 total net revenue of $49.7 million, a 17% increase year-over-year, driven by a 34% increase in U.S. net product revenue to $40.9 million. The company's operating loss significantly improved to $11.1 million, 56% lower than Q3 2024.
- The company has transitioned to a fully partnered commercial model across international ex-U.S. markets, with Recordati expected to fully manage European commercialization by the end of 2025. This strategic shift, combined with an organizational restructuring, is projected to yield $70 million in OpEx savings over the next year.
- Amarin maintains over 50% share of the U.S. IPE market and regained exclusive status with a large national pharmacy benefit manager, expecting to retain major exclusives through at least the end of 2025.
- The company anticipates achieving positive free cash flow in 2026 and ended Q3 2025 with $286.6 million in cash and investments and no debt.
- The FDA's recent revision of phenofibrate labeling, highlighting a lack of cardiovascular benefit, is seen by Amarin as a critical step that could shift clinical practice towards proven therapies like VASCEPA.
Oct 29, 2025, 12:00 PM
Amarin Reports Q3 2025 Financial Results
AMRN
Earnings
Layoffs
Guidance Update
- Amarin reported Total Net Revenue of $49.7 million for Q3 2025, an increase of 17% compared to Q3 2024, primarily driven by higher U.S. sales.
- Operating Expenses decreased 20% to $33.3 million in Q3 2025, leading to an Operating Loss of $11.1 million, a 56% improvement from Q3 2024, largely due to the June 2025 restructuring.
- The company's Net Loss for Q3 2025 was $7.7 million, or $0.02 per share, representing a 69% improvement compared to Q3 2024.
- Amarin held $286.6 million in cash and investments at the end of Q3 2025.
- The company is targeting sustainable positive free cash flow in 2026 and has completed its transition to a fully partnered commercialization model across all international markets.
Oct 29, 2025, 11:05 AM
Quarterly earnings call transcripts for AMARIN CORP PLC\UK.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more